Social Media Ideas for Abbv

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

The pharmaceutical company hopes that another big-time acquisition will pay off.

Going Deeper On Disc Medicine

Should You Buy AbbVie Stock Hand Over Fist Before July 31?

The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year

AbbVie has another blockbuster business emerging.

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

It looks like a great buy-and-hold option.

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

There's no need to panic.

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)

Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?

These two high-quality dividend payers have had very different fortunes recently.

Abbott raises 2026 profit forecast on strength in diagnostics, heart devices

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

AbbVie released positive phase 3 data Thursday showing that its bispecific T-cell engager etentamig improved response rates and progression-free survival in patients with relapsed/...

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

Trailing rivals, AbbVie scores win with dual-acting myeloma drug

The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.

<![CDATA[M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration wit...

Abeona (ABEO) Q2 2026 Earnings Call Transcript

ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded.

My 2 Favorite Dividend Kings to Buy Right Now

They can help stabilize your portfolio in these otherwise volatile times.

Abbott launches ready-to-feed whole milk infant formula

Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch

Why AbbVie Stock Slumped Today

The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.